Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioequivalence testing

Demana, Patrick H; Smith, Eric W; Walker, Roderick B; Haigh, John M; Kanfer, Isadore

Title: Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioequivalence testing
Creator: Demana, Patrick H
Creator: Smith, Eric W
Creator: Walker, Roderick B
Creator: Haigh, John M
Creator: Kanfer, Isadore
Date Issued: 1997
Date: 1997
Type: Article
Identifier: vital:6356
Identifier: http://hdl.handle.net/10962/d1006047
Description: The American FDA has recently released a Guidance document for topical corticosteroid bioequivalence testing. The purpose of this study was to evaluate the recommendations of this document for appropriateness. The new specifications require a dose-vasoconstriction response estimation by the use of a Minolta chromameter in a preliminary pilot study to determine the parameters for use in a pivotal bioequivalence study. Methods. The visually-assessed human skin blanching assay methodology routinely practiced in our laboratories was modified to comply with the requirements of the pilot study so that visual and chromameter data could be compared. Two different cream formulations, each containing 0.12% betamethasone 17-valerate, were used for this comparison. Results. Visual data showed the expected rank order of AUC values for most dose durations whereas the chromameter data did not show similar results. The expected rank order of AUC values for both chromameter and visual data was not observed at very short dose durations. In fitting the data to pharmacodynamic models, equivalent goodness of fit criteria were obtained when several different parameter estimates were used in the model definition, however the visual data were best described by the sigmoid E[subscript max] model while the chromameter data were best described by the simple E[subscript max] model. Conclusions. The E[subscript max] values predicted by the models were close to the observed values for both data sets and, in addition, excellent correlation between the AUC values and the maximum blanching response (R[subscript max]) (r > 0.95) was noted for both methods of assessment. The chromameter ED[subscript 50] values determined in this study were approximately 2 hours for both preparations. At this dose duration the instrument would not be sensitive enough to distinguish between weak blanching responses and normal skin for bioequivalence assessment purposes.
Format: 6 pages
Format: pdf
Language: English
Relation: Demana, P.H. and Smith, E.W. and Walker, R.B. and Haigh, J.M. and Kanfer, I. (1997) Evaluation of the proposed FDA pilot-dose response methodology for topical corticosteroid bioequivalence testing. Pharmaceutical Research, 14 (3). pp. 179-183. Available: http://dx.doi.org/10.1023/A:1012089803281

Hits: 1843
Visitors: 1945
Downloads: 145

Collections

Walker, Roderick Bryan (Prof)

Kanfer, Isadore (Prof)

Haigh, John M (Prof)

RU Department of Pharmacy

SDG 03. Good Health and Well-Being

		Thumbnail	File	Description	Size	Format
View Details Download			SOURCEPDF	PDF	542 KB	Adobe Acrobat PDF	View Details Download